Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
This quarterly report represents an earnings surprise of -413.95%. A quarter ago, it was expected that this genome editing company would post a loss of $0.42 per share when it actually produced a loss of $3.20, delivering a surprise of -661.90%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Precision BioSciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 99.71%. This compares to year-ago revenues of $17.58 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Precision BioSciences shares have added about 29.9% since the beginning of the year versus the S&P 500's gain of 0.2%.
While Precision BioSciences has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Precision BioSciences: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $13.7 million in revenues for the coming quarter and -$1.17 on $45.6 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Fortress Biotech (FBIO), another stock in the same industry, has yet to report results for the quarter ended March 2025.
This biopharmaceutical company is expected to post quarterly loss of $0.44 per share in its upcoming report, which represents a year-over-year change of +57.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Fortress Biotech's revenues are expected to be $10.3 million, down 21% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report
Fortress Biotech, Inc. (FBIO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Alphabet Inc. (GOOG) Q2 Earnings and Revenues Top Estimates
Alphabet Inc. (GOOG) came out with quarterly earnings of $5.12 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $1.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +138.14%. A quarter ago, it was expected that this company would post earnings of $2.02 per share when it actually produced earnings of $2.81, delivering a surprise of +39.11%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Alphabet, which belongs to the Zacks Internet - Services industry, posted revenues of $81.72 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.82%. This compares to year-ago revenues of $71.36 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Alphabet shares have added about 0.9% since the beginning of the year versus the S&P 500's gain of 7.3%. What's Next for Alphabet? While Alphabet has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Alphabet was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.20 on $82.63 billion in revenues for the coming quarter and $9.57 on $329.15 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Services is currently in the bottom 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. DoorDash, Inc. (DASH), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 6. This company is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +210.5%. The consensus EPS estimate for the quarter has been revised 0.7% higher over the last 30 days to the current level. DoorDash, Inc.'s revenues are expected to be $3.16 billion, up 20.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOG) : Free Stock Analysis Report DoorDash, Inc. (DASH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Bloomberg
35 minutes ago
- Bloomberg
Stocks Gain, Havens Retreat on Trade Deal Optimism: Markets Wrap
Asian equities were set to climb Thursday after a US trade deal with Japan and signs of another with the European Union injected fresh vigor into stocks. Haven assets retreated. Equity index futures for Japan and Australia climbed, with contracts for Tokyo benchmarks up more than 1% early Thursday in Asia. The S&P 500 ended Wednesday 0.8% higher to set a third consecutive daily closing record, while Alphabet Inc. shares climbed in after-hours trading after reporting better-than-expected revenue.
Yahoo
37 minutes ago
- Yahoo
Exxon Mobil (XOM) Surpasses Market Returns: Some Facts Worth Knowing
Exxon Mobil (XOM) closed the most recent trading day at $109.85, moving +1.21% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78%. Elsewhere, the Dow gained 1.14%, while the tech-heavy Nasdaq added 0.61%. Heading into today, shares of the oil and natural gas company had gained 0.18% over the past month, outpacing the Oils-Energy sector's loss of 3.19% and lagging the S&P 500's gain of 5.88%. The investment community will be closely monitoring the performance of Exxon Mobil in its forthcoming earnings report. The company is scheduled to release its earnings on August 1, 2025. In that report, analysts expect Exxon Mobil to post earnings of $1.49 per share. This would mark a year-over-year decline of 30.37%. Meanwhile, the latest consensus estimate predicts the revenue to be $82.84 billion, indicating a 10.98% decrease compared to the same quarter of the previous year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.57 per share and a revenue of $334.4 billion, representing changes of -15.66% and -4.34%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Exxon Mobil. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 7.51% higher within the past month. Exxon Mobil is currently sporting a Zacks Rank of #3 (Hold). With respect to valuation, Exxon Mobil is currently being traded at a Forward P/E ratio of 16.53. This valuation marks a premium compared to its industry average Forward P/E of 11.25. It is also worth noting that XOM currently has a PEG ratio of 2.02. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Oil and Gas - Integrated - International was holding an average PEG ratio of 1.99 at yesterday's closing price. The Oil and Gas - Integrated - International industry is part of the Oils-Energy sector. With its current Zacks Industry Rank of 188, this industry ranks in the bottom 24% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
